Are you curious about cutting-edge advancements in NASH disease research?

Apr 22, 2024 10:00am ET

Join us for an exciting look at the innovative new drug R&D strategies behind a novel NAFLD/NASH animal model. See how this recent development delivers key insights into liver diseases as it mirrors real patient experiences. We’ll take a deep dive into in vitro phenotypic models, the utilization of human cells, and the effects of Resmetirom on inhibiting fat accumulation.

What to Expect:

See firsthand how this model aligns with clinical trial studies for confident results
Learn how to gain key NASH indicators in just 12-16 weeks
Discover the significant cost and time savings in comparison to traditional methods

Watch On-Demand

Learn about our Speaker
John Liu
Head of Pharmacology, Discovery BioDuro-Sundia
Yongqiang Liu (John), with 18 years in drug discovery and CRO operations, leads the pharmacology department at BioDuro-Sundia since 2019. His focus spans immunology, inflammation, neurodegeneration, cardiovascular, and metabolic diseases. Formerly at CrownBio for 8 years, he excelled in cardiovascular and metabolic diseases, contributing to oncology studies. Noteworthy achievements include leading R&D projects and external studies. In 2008-2011, John Liu worked on GPCR-related drug research at Argusina, and earlier, he successfully managed a clinical trial-approved drug project at Wolwo Biotech. With expertise in NASH, he dedicates over a decade to NASH animal model development, accumulating 10+ years of experience. Author of 8 peer-reviewed publications.
Lin Teng
Vice President of Integrated Biology, Discovery
With 15 years of drug development research experience in top pharmaceutical companies and CROs, Lin Teng excels in target identification/validation, assay development, pre-clinical studies, translational research, and mechanism exploration. Lin Teng gained her Ph.D. from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, and joined BioDuro-Sundia in 2020. As the head of Integrated Biology, she leads global collaborations, overseeing the development of comprehensive assays and screening compounds for all major drug target classes. Lin Teng previously contributed to Novartis and Johnson & Johnson, focusing on epigenetic drugs for oncology and hematological malignancies. With 9 peer-reviewed publications, Lin Teng continues to drive impactful advancements in drug development.
Register now !
June 19, 10:00am ET/07:00am PT/04:00pm CET New modality - Peptides Innovations and A Comprehensive Synthetic Peptide Drug Discovery Platform
View more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all